• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

MRP1 启动子多态性与肝癌患者生存时间降低相关。

Promoter polymorphism of MRP1 associated with reduced survival in hepatocellular carcinoma.

机构信息

Key Laboratory of Gene Engineering of the Ministry of Education, School of Life Sciences, Sun Yat-sen (Zhongshan) University, Xin Gang Xi Road 135#, Guangzhou 510275, Guangdong Province, China.

出版信息

World J Gastroenterol. 2010 Dec 28;16(48):6104-10. doi: 10.3748/wjg.v16.i48.6104.

DOI:10.3748/wjg.v16.i48.6104
PMID:21182225
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3012574/
Abstract

AIM

to investigate the effect of the G-1666A polymorphism in the multidrug resistance related protein-1 (MRP1) on outcome of hepatocellular carcinoma (HCC).

METHODS

a cohort of 162 patients with surgically resected HCC who received no postsurgical treatment until relapse was studied. Genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism analysis. Electrophoretic mobility shift assay (EMSA) was used to evaluate the influence of the G-1666A polymorphism on the binding affinity of the MRP1 promoter with its putative transcription factors.

RESULTS

Kaplan-Meier analysis showed that patients with GG homologues had a reduced 4-year disease-free survival compared with those carrying at least one A allele (P = 0.011). Multivariate Cox regression analysis indicated that the -1666GG genotype represented an independent predictor of poorer disease-free survival [hazard ratio (HR) = 3.067, 95% confidence interval (CI): 1.587-5.952, P = 0.001], and this trend became worse in men (HR = 3.154, 95% CI: 1.604-6.201, P = 0.001). A similar association was also observed between 4-year overall survival and the polymorphism in men (HR = 3.342, 95% CI: 1.474-7.576, P = 0.004). Moreover, EMSA suggested that the G allele had a stronger binding affinity to nuclear proteins.

CONCLUSION

the MRP1 -1666GG genotype predicted a worse outcome and was an independent predictor of poor survival in patients with HCC from Southeast China.

摘要

目的

探讨多药耐药相关蛋白 1(MRP1)中的 G-1666A 多态性对肝细胞癌(HCC)患者预后的影响。

方法

研究了 162 例接受手术切除且术后未接受任何治疗直至复发的 HCC 患者。通过聚合酶链反应-限制性片段长度多态性分析进行基因分型。电泳迁移率变动分析(EMSA)用于评估 G-1666A 多态性对 MRP1 启动子与其假定转录因子结合亲和力的影响。

结果

Kaplan-Meier 分析表明,与携带至少一个 A 等位基因的患者相比,GG 同型患者的 4 年无疾病生存率降低(P = 0.011)。多变量 Cox 回归分析表明,-1666GG 基因型是无疾病生存率较差的独立预测因子[风险比(HR)= 3.067,95%置信区间(CI):1.587-5.952,P = 0.001],这种趋势在男性中更为明显(HR = 3.154,95%CI:1.604-6.201,P = 0.001)。该多态性与男性患者的 4 年总生存率之间也存在类似的关联(HR = 3.342,95%CI:1.474-7.576,P = 0.004)。此外,EMSA 表明 G 等位基因与核蛋白具有更强的结合亲和力。

结论

MRP1-1666GG 基因型预示着更差的结局,是中国东南部 HCC 患者生存不良的独立预测因子。

相似文献

1
Promoter polymorphism of MRP1 associated with reduced survival in hepatocellular carcinoma.MRP1 启动子多态性与肝癌患者生存时间降低相关。
World J Gastroenterol. 2010 Dec 28;16(48):6104-10. doi: 10.3748/wjg.v16.i48.6104.
2
A novel functional polymorphism in the Cdc6 promoter is associated with the risk for hepatocellular carcinoma.细胞分裂周期蛋白6(Cdc6)启动子中的一种新型功能多态性与肝细胞癌风险相关。
Mutat Res. 2008 Aug 25;643(1-2):70-4. doi: 10.1016/j.mrfmmm.2008.06.006. Epub 2008 Jul 1.
3
MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.MDM2 启动子多态性与土耳其人群肝癌易感性增加相关。
Cancer Epidemiol. 2010 Aug;34(4):448-52. doi: 10.1016/j.canep.2010.04.008. Epub 2010 May 5.
4
Study on the DNA repair gene XRCC1 and XRCC3 polymorphism in prediction and prognosis of hepatocellular carcinoma risk.DNA修复基因XRCC1和XRCC3多态性在预测肝细胞癌风险及预后中的研究
Hepatogastroenterology. 2012 Oct;59(119):2285-9. doi: 10.5754/hge12096.
5
PD1 gene polymorphism is associated with a poor prognosis in hepatocellular carcinoma following liver resection, cohort study.PD1 基因多态性与肝切除术后肝细胞癌预后不良相关:队列研究。
Int J Surg. 2020 Aug;80:84-90. doi: 10.1016/j.ijsu.2020.05.007. Epub 2020 Jun 29.
6
Donor Polymorphisms of Toll-like Receptor 4 rs1927914 Associated with the Risk of Hepatocellular Carcinoma Recurrence Following Liver Transplantation.供体 Toll 样受体 4 rs1927914 多态性与肝移植后肝细胞癌复发的风险相关。
Arch Med Res. 2017 Aug;48(6):553-560. doi: 10.1016/j.arcmed.2017.11.011. Epub 2017 Dec 6.
7
Mannose-binding lectin 2 rs11003123 polymorphism is associated with the development of hepatocellular carcinoma in patients with hepatitis B-related cirrhosis in the Chinese population.甘露糖结合凝集素2基因rs11003123多态性与中国人群乙型肝炎相关肝硬化患者肝细胞癌的发生有关。
Hepatobiliary Pancreat Dis Int. 2016 Jun;15(3):282-8. doi: 10.1016/s1499-3872(16)60050-4.
8
Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.神经胶质抗原2在肝细胞癌中的过表达预示预后不良。
World J Gastroenterol. 2015 Jun 7;21(21):6649-59. doi: 10.3748/wjg.v21.i21.6649.
9
Genetic variants of cell cycle pathway genes predict disease-free survival of hepatocellular carcinoma.细胞周期通路基因的遗传变异可预测肝细胞癌的无病生存期。
Cancer Med. 2017 Jul;6(7):1512-1522. doi: 10.1002/cam4.1067. Epub 2017 Jun 22.
10
A genetic variant in the promoter of CD46 is associated with the risk and prognosis of hepatocellular carcinoma.CD46 启动子中的遗传变异与肝细胞癌的风险和预后相关。
Mol Carcinog. 2020 Nov;59(11):1243-1255. doi: 10.1002/mc.23252. Epub 2020 Sep 1.

引用本文的文献

1
FXR, MRP-1 and SLC7A5: New Targets for the Treatment of Hepatocellular Carcinoma.FXR、MRP-1 和 SLC7A5:肝细胞癌治疗的新靶点。
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241276889. doi: 10.1177/15330338241276889.
2
Investigation of the effects of catharanthine and Q10 on Nrf2 and its association with MMP-9, MRP1, and Bcl-2 and apoptosis in a model of hepatocellular carcinoma.研究苦参碱和 Q10 对 Nrf2 的影响及其与 MMP-9、MRP1 和 Bcl-2 的关系以及肝癌模型中的细胞凋亡。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Apr;397(4):2507-2522. doi: 10.1007/s00210-023-02767-0. Epub 2023 Oct 19.
3
Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma.肝细胞癌和胆管癌的药物遗传学
Cancer Drug Resist. 2019 Sep 19;2(3):680-709. doi: 10.20517/cdr.2019.006. eCollection 2019.
4
Association of Two Polymorphic Codons in and Promoter with Prostate Cancer.[基因名称]和[基因名称]启动子中两个多态密码子与前列腺癌的关联。 (你提供的原文中基因名称缺失,请补充完整后我能给出更准确译文)
Iran J Biotechnol. 2015 Mar;13(1):49-54. doi: 10.15171/ijb.1096.
5
Effect of Liver Disease on Hepatic Transporter Expression and Function.肝脏疾病对肝转运体表达及功能的影响。
J Pharm Sci. 2017 Sep;106(9):2282-2294. doi: 10.1016/j.xphs.2017.04.053. Epub 2017 Apr 30.
6
Silencing MRP1-4 genes by RNA interference enhances sensitivity of human hepatoma cells to chemotherapy.通过RNA干扰使多药耐药相关蛋白1-4基因沉默可增强人肝癌细胞对化疗的敏感性。
Am J Transl Res. 2016 Jun 15;8(6):2790-802. eCollection 2016.
7
Association of the human astrocyte elevated gene-1 promoter variants with susceptibility to hepatocellular carcinoma.人类星形胶质细胞升高基因-1启动子变体与肝细胞癌易感性的关联。
Med Oncol. 2014 Apr;31(4):916. doi: 10.1007/s12032-014-0916-5. Epub 2014 Mar 22.
8
Regulatory mechanism of ZNF139 in multi-drug resistance of gastric cancer cells.ZNF139在胃癌细胞多药耐药中的调控机制
Mol Biol Rep. 2014 Jun;41(6):3603-10. doi: 10.1007/s11033-014-3224-4. Epub 2014 Feb 11.
9
The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy.活性药物细胞内浓度降低在抗癌化疗反应缺乏中的作用。
Acta Pharmacol Sin. 2014 Jan;35(1):1-10. doi: 10.1038/aps.2013.131. Epub 2013 Dec 9.
10
Multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphism: from discovery to clinical application.多药耐药相关蛋白1(MRP1/ABCC1)多态性:从发现到临床应用
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011 Oct;36(10):927-38. doi: 10.3969/j.issn.1672-7347.2011.10.002.

本文引用的文献

1
Characterization and analyses of multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphisms in Chinese population.中国人群中多药耐药相关蛋白1(MRP1/ABCC1)基因多态性的特征分析
Pharmacogenet Genomics. 2009 Mar;19(3):206-16. doi: 10.1097/FPC.0b013e328323f680.
2
The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma.调节性BCL2启动子多态性(-938C>A)与口咽鳞状细胞癌患者的复发和生存相关。
Ann Oncol. 2009 Jun;20(6):1094-9. doi: 10.1093/annonc/mdn763. Epub 2009 Feb 5.
3
MRP1 polymorphisms (T2684C, C2007T, C2012T, and C2665T) are not associated with multidrug resistance in leukemic patients.多药耐药相关蛋白1(MRP1)基因多态性(T2684C、C2007T、C2012T和C2665T)与白血病患者的多药耐药性无关。
Genet Mol Res. 2008;7(4):1369-74. doi: 10.4238/vol7-4gmr482.
4
A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma.miR-146a基因中的功能性多态性与肝细胞癌风险相关。
Carcinogenesis. 2008 Nov;29(11):2126-31. doi: 10.1093/carcin/bgn195. Epub 2008 Aug 18.
5
A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients.一种多药耐药基因1(ABCB1)单核苷酸多态性可预测胶质母细胞瘤患者替莫唑胺治疗的结果。
Ann Oncol. 2009 Jan;20(1):175-81. doi: 10.1093/annonc/mdn548. Epub 2008 Aug 7.
6
Large-scale analysis of the genetic and epigenetic alterations in hepatocellular carcinoma from Southeast China.中国东南部肝细胞癌基因和表观遗传改变的大规模分析
Mutat Res. 2008 May 10;641(1-2):27-35. doi: 10.1016/j.mrfmmm.2008.02.005. Epub 2008 Feb 14.
7
ABC multidrug transporters: structure, function and role in chemoresistance.ABC多药转运蛋白:结构、功能及在化疗耐药中的作用
Pharmacogenomics. 2008 Jan;9(1):105-27. doi: 10.2217/14622416.9.1.105.
8
Prognosis in patients with hepatocellular carcinoma correlates to mutations of p53 and/or hMSH2 genes.肝细胞癌患者的预后与p53和/或hMSH2基因的突变相关。
Eur J Cancer. 2007 Apr;43(6):1092-100. doi: 10.1016/j.ejca.2007.01.032. Epub 2007 Mar 12.
9
A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans.p53 通路中的单核苷酸多态性与性别、环境应激和肿瘤遗传学相互作用,从而影响人类癌症。
Oncogene. 2007 Feb 26;26(9):1317-23. doi: 10.1038/sj.onc.1210199.
10
Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer.晚期卵巢癌耐药相关基因单核苷酸多态性与化疗反应的相关性
Anticancer Res. 2006 May-Jun;26(3B):2227-32.